US President Donald Trump recently signed an executive order to increase access to certain psychedelic substances for mental health treatments like depression and anxiety. This new directive allocates $50 million in federal funds to make these therapies more available. The order also tells the Food and Drug Administration (FDA) to speed up its review process for substances such as psilocybin and ibogaine.
According to NPR, this move is part of a broader push to fast-track the evaluation of psychedelic-assisted treatments. During the signing ceremony, Trump was joined by Health and Human Services Secretary Robert F. Kennedy Jr. and Dr. Mehmet Oz, head of the Centers for Medicare and Medicaid Services.
Next week, the FDA plans to issue national priority vouchers for three psychedelic drugs. Its commissioner, Mary Makary, mentioned that this could allow for quicker reviews, possibly completing them in just a few weeks. This would be the first time the FDA has expedited the approval process for these substances.
During the event, Trump addressed the national mental health crisis, mentioning that over 14 million adults in the U.S. struggle with serious mental illnesses, with about 8 million relying on prescription medication for help. He highlighted promising results from studies using psychedelics on active-duty military personnel and veterans dealing with post-traumatic stress disorder (PTSD). The Department of Veterans Affairs is currently running at least five clinical trials involving psychedelics across states like New York, California, and Oregon.
Psychedelics are known to cause changes in perception and mood. They are gaining attention not only for their therapeutic potential but also for how they differ from traditional medications. Experts believe that while these substances show promise, more research is necessary to fully understand their effects and long-term safety.
Recent studies indicate a shift in public perception toward psychedelics. A survey found that nearly 60% of Americans now believe these substances can be used safely in mental health treatments. This change might reflect a growing acknowledgment of the mental health crisis in the country, especially in light of rising suicide rates and the ongoing COVID-19 pandemic.
As this initiative unfolds, the impact on mental health treatment could be significant. Increased access to psychedelics may offer hope to many individuals seeking alternative therapies, especially those who have not found relief through conventional methods.
For more detailed information about the FDA’s work on psychedelic substances, check this FDA report.
Source link
SiteKeywords
